The therapeutic strategy of a tissue‐specific requirement for immunoglobulin Mu DNA binding protein 2 (IGHMBP2) has been verified effectively in cardiomyocyte maintenance and survival, and a genetic modifier has been found that it can alter the course of DCM through cardiac functional adaptation and physical remodeling.249. Here, IGHMBP2 is linked to familial dilated cardiomyopathy.